Evidence map›Paper›PMID 29362422›Full record

ArticleCell death & disease2018

A caspase-2-RFXANK interaction and its implication for MHC class II expression.

Jeremy Forsberg, Xinge Li, Birce Akpinar, Roger Salvatori, Martin Ott, Boris Zhivotovsky, Magnus Olsson

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Genes · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jeremy ForsbergDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Xinge LiDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Birce AkpinarDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Roger SalvatoriDepartment of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.
Martin OttDepartment of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden.
Boris ZhivotovskyDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Boris.Zhivotovsky@ki.se.
Magnus OlssonDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6370-8423
Karolinska Institutet · SEStockholm University · SEScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent achievements implicating caspase-2 in tumor suppression, the enzyme stands out from the apoptotic caspase family as a factor whose function requires further clarification. To specify enzyme characteristics through the definition of interacting proteins in apoptotic or non-apoptotic settings, a yeast 2-hybrid (Y2H) screen was performed using the full-length protein as bait. The current report describes the analysis of a captured prey and putative novel caspase-2 interacting factor, the regulatory factor X-associated ankyrin-containing protein (RFXANK), previously associated with CIITA, the transactivator regulating cell-type specificity and inducibility of MHC class II gene expression. The interaction between caspase-2 and RFXANK was verified by co-immunoprecipitations using both exogenous and endogenous proteins, where the latter approach suggested that binding of the components occurs in the cytoplasm. Cellular co-localization was confirmed by transfection of fluorescently conjugated proteins. Enhanced caspase-2 processing in RFXANK-overexpressing HEK293T cells treated with chemotherapeutic agents further supported Y2H data. Yet, no distinct differences with respect to MHC class II expression were observed in plasma membranes of antigen-presenting cells derived from wild type and caspase-2

Indexed as

AnimalsBlood CellsCaspase 2Cell MembraneDNA-Binding ProteinsDoxorubicinFluorouracilHCT116 CellsHEK293 CellsHistocompatibility Antigens Class IIHumansMice, Inbred C57BLProtein BindingProteolysisReproducibility of ResultsSaccharomyces cerevisiaeCaspase 2DNA-Binding ProteinsDoxorubicinFluorouracilHistocompatibility Antigens Class IIRFXANK protein, humanTranscription Factors

Identifiers

PMID29362422
PMCPMC5833739
OpenAlexW2793297666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.